Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Gastroenterology & Hepatology
Thomas X. Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba
Summary: In this meta-analysis of randomized controlled studies, patients with IBD who took PPIs were less likely to achieve remission while on infliximab therapy. Further investigation into the effect of PPIs on IBD outcomes and therapies is warranted based on our study's results.
Article
Gastroenterology & Hepatology
Shaden Mahmmod, Johannes P. D. Schultheiss, Ad A. van Bodegraven, Gerard Dijkstra, Lennard P. L. Gilissen, Frank Hoentjen, Maurice W. M. D. Lutgens, Nofel Mahmmod, Andrea E. Van der Meulen-de Jong, Lisa J. T. Smits, Adriaan C. I. T. L. Tan, Bas Oldenburg, Herma H. Fidder
Summary: In a retrospective multicenter cohort study, about 9.9% of IBD patients who were switched from originator infliximab to biosimilar CT-P13 experienced reverse switching, predominantly due to biosimilar-attributed adverse effects. Some patients showed symptom improvement after reverse switching, with a good response seen in those who had lost response to CT-P13.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Review
Gastroenterology & Hepatology
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Summary: This study assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs). The results showed that switching from intravenous to subcutaneous infliximab was safe and well accepted, with a low risk of relapse in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Pediatrics
Kaija-Leena Kolho
Summary: The prevalence of pediatric-onset inflammatory bowel disease (IBD) has been increasing in recent decades, leading to a rise in patients with moderate to severe disease subtype treated with TNF alpha antagonists. While most pediatric patients initially respond to these drugs, dose escalation may be required during the first year of therapy. Due to limited data on therapeutic drug monitoring during therapy with the TNF alpha-blocker adalimumab in pediatric patients, this review focuses on the literature on therapeutic drug monitoring of infliximab and its potential to guide management.
FRONTIERS IN PEDIATRICS
(2021)
Article
Gastroenterology & Hepatology
Camilla de Almeida Martins, Matheus Freitas Cardoso de Azevedo, Alexandre Sousa Carlos, Aderson Omar Mourao Cintra Damiao, Carlos Walter Sobrado Jr, Sergio Carlos Nahas, Natalia Sousa Freitas Queiroz
Summary: This study has enhanced our understanding of the predictive factors of treatment response to IFX in a well-characterized Brazilian IBD population. The study found that the duration of IFX therapy and higher albumin levels increased the likelihood of clinical remission, while previous surgery decreased its chance. Prior use of adalimumab and higher C-reactive protein levels reduced the likelihood of endoscopic remission.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Miikka Hoyhtya, Katri Korpela, Schahzad Saqib, Sofia Junkkari, Eija Nissila, Anne Nikkonen, Evgenia Dikareva, Anne Salonen, Willem M. de Vos, Kaija-Leena Kolho
Summary: This study aimed to investigate the absolute abundances of gut microbiota in relation to the response to induction therapy with infliximab in pediatric inflammatory bowel disease. The results showed that the treatment responsive group had a higher absolute abundance of Bifidobacteriales and a lower absolute abundance of Actinomycetales compared to the nonresponders. However, the level of inflammation according to fecal calprotectin showed no statistically significant association with the absolute abundances of fecal microbiota. The results on relative abundances differed from the absolute abundances.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Tommaso Lorenzo Parigi, Ferdinando D'Amico, Maria Abreu, Axel Dignass, Iris Dotan, Fernando Magro, Anne M. Griffiths, Vipul Jairath, Marietta Iacucci, Gerassimos J. Mantzaris, Colm O'Morain, Walter Reinisch, David B. Sachar, Dan Turner, Takayuki Yamamoto, David Rubin, Laurent Peyrin-Biroulet, Subrata Ghosh, Silvio Danese
Summary: Under the guidance of the International Organization for the Study of Inflammatory Bowel Disease, a consensus meeting was held to propose a common operative definition for difficult-to-treat IBD. Difficult-to-treat IBD is defined by the failure of biologics and advanced small molecules with at least two different mechanisms of action, or postoperative recurrence of Crohn's disease after two surgical resections in adults, or one in children. Chronic antibiotic-refractory pouchitis, complex perianal disease, and comorbid psychosocial complications that impair disease management also qualified as difficult-to-treat IBD.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Rheumatology
Camille Rasmussen, Vered Abitbol, Khalil El Karoui, Anne Bourrier, Romain Paule, Lucine Vuitton, Francois Maurier, David Laharie, Mathurin Fumery, Christian Agard, Michael Collins, Stephane Nancey, Cedric Rafat, Anne-Gaelle Kervegant, Viviane Queyrel-Moranne, Guillaume Moulis, Benedicte Pigneur, Alexis Regent, Claire Gay, Caroline Morbieu, Cecile Audrey Durel, Didier Ducloux, Francois Aubin, Mickaela Voicu, Nizar Joher, Tali Szwebel, Marie-Christine Martinez Vinson, Stephane Koch, Loic Guillevin, Laurent Peyrin-Biroulet, Benjamin Terrier
Summary: The study suggests that TNF-alpha blockers may promote the onset of IgAV in patients with IBD. Discontinuation of anti-TNF-alpha is associated with vasculitis remission but increased risk of IBD relapses, while continuation of anti-TNF-alpha is associated with IBD remission but potential vasculitis relapse.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)